Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2023

Dagogo-Jack Ibiayi, Kiedrowski Lesli A, Lennerz Jochen K

Abstract excerpt

OBJECTIVES: MET amplification is a common mechanism of resistance to second- and third-generation anaplastic lymphoma kinase (ALK) inhibitors. In case series of MET-amplified ALK-rearranged (ALK + ) lung cancer, durability of responses to combinations targeting ALK and MET is variable, suggesting heterogeneity across tumors. However, little is known about the molecular composition of this subset of ALK-rearranged...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37813016
DOI: 10.1016/j.lungcan.2023.107383

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.PMID 37813016Read ↗

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogiesSemantic proximity Read ↗

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsSemantic proximity Read ↗

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.Semantic proximity Read ↗

Crizotinib in Patients With MET-Amplified NSCLC.Semantic proximity Read ↗

Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation.Semantic proximity Read ↗

Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.Semantic proximity Read ↗

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.Semantic proximity Read ↗

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLCSemantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

Targeting MET in EGFR-Mutated NSCLC.Semantic proximity Read ↗

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.